Diagnosis and management of superficial bladder cancer

Current Problems in Cancer

Volumn 25, Issue 4, 2001, Pages IN1-IN2

  Amling, Christopher L ^a,b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AROMATIC AMINE; BCG VACCINE; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN C; THIOTEPA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CIGARETTE SMOKING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC IMAGING; HEMATURIA; HIGH RISK PATIENT; HUMAN; INTRAVENOUS PYELOGRAPHY; META ANALYSIS; OCCUPATIONAL EXPOSURE; PHOTODYNAMIC THERAPY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; ULTRASOUND; ADULT; AGED; BLADDER TUMOR; BLOOD GROUP ABO SYSTEM; CANCER STAGING; DIFFERENTIAL DIAGNOSIS; FEMALE; IMMUNOTHERAPY; INCIDENCE; INTRAVESICAL DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHOTOCHEMOTHERAPY; SURGERY; TRANSITIONAL CELL CARCINOMA; URETHRA;

ABO BLOOD-GROUP SYSTEM; ADMINISTRATION, INTRAVESICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMATURIA; HUMANS; IMMUNOTHERAPY; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; RISK FACTORS; SURGICAL PROCEDURES, OPERATIVE; TUMOR MARKERS, BIOLOGICAL; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 0034822163     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcn.2001.117539     Document Type: Review

References (179)

1. Cancer statistics, 2001
2. Epidemiology of bladder cancer
3. The natural history of bladder cancer; implications for therapy
4. Natural history of superficial bladder cancer: Prognostic features and long-term disease course
5. Occupational risks of bladder cancer in the United States. - II: Nonwhite men
6. Occupational risks of bladder cancer in the United States. I. White men
7. Blasengeschwulste bei fuchsin-arbeitern
8. Experimental production of bladder tumors in dogs by administration of beta-naphthylamine
9. Concepts in causality: Chemically induced human urinary bladder cancer
10. N-acetyl-transferase phenotypes in the urinary bladder cacinogenisis of a low risk population
11. Carcinogen hemoglobin adducts, urinary mutagenicity, and metabolic phenotype in active and passive cigarette smokers
12. The association of smoking with cancer of the urinary bladder in humans
13. Tobacco and bladder cancer in males: Increased risk for inhalers and smokers of black tobacco
14. Changing cigarette habits and bladder cancer risk: A case control study
15. Smoking-related carcinogen-DNA adducts in biopsy samples of human urinary bladder: Identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct
16. Bladder cancer after chemotherapy for non-Hodgkin's lymphoma
17. Radiation dose and second cancer risk in patients treated for cancer of the cervix
18. Second primary malignancies in TI-3N0 prostate cancer patients treated with radiation therapy with 10-year follow-up
19. Histopathology and classification of urinary bladder carcinoma
20. Screening cytoscopy and survival of spinal cord injured patients with squamous cell cancer of the bladder
21. Pathology of carcinomas of the urinary bladder
22. Primary adenocarcinoma of the urinary bladder: A clinicopathologic analysis of 72 cases
23. Muscularis mucosa differentiates two populations with different prognosis in stage TI bladder cancer
24. The usefulness of the level of the muscularis mucosae in the in the staging of invasive transitional cell carcinoma of the urinary bladder
25. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasm of the urinary bladder
26. Haematuria diagnostic service
27. Clinical importance of microhematuria
28. Asymptomatic microscopic hematuria
29. Asymptomatic microhematuria and urologic disease: A population-based study
30. Prospective comparison of computed tomography and intravenous pyelography in the initial evaluation of asymptomatic microhematuria
31. CT in determining depth of infiltration of bladder tumors
32. What is new in bladder cancer imaging
33. New methods for detection of bladder cancer
34. Comparison of screening methods in the detection of bladder cancer
35. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma
36. Urine cytology: Is it still the gold standard for screening
37. Superficial bladder cancer: Progression and recurrence
38. Urinary cytology and bladder cancer: The cellular features of transitional cell neoplasms
39. Low grade transitional cell carcinoma of the bladder: Cytologic diagnosis by key features as identified by logistic regression analysis
40. Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during follow-up for bladder tumors
41. Editorial: Do we have a prostate specific antigen for bladder cancer?
42. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer
43. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder
44. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms
45. Noninvasivc detection of bladder cancer with the BTA stat test
46. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors
47. Use of the new tumor marker, urinary NMP22, in the detection of occult or rapidily recurring transitional cell carcinoma of the urinary tract following surgical treatment
48. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder
49. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer
50. The HA-Haase urine test: A sensitive and specific method for detecting bladder cancer and evaluating its grade
51. New methods for detection of bladder cancer
52. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
53. Natural history of early bladder cancer
54. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15 Year outcome
55. Carcinoma in situ
56. Flat carcinoma in situ of bladder
57. Displasia in normal looking urothelium increases the risk of tumor progression in primary superficial bladder cancer
58. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ
59. Bacillus Calmette-Guerin therapy for superficial bladder cancer: A 10 year follow-up
60. Superficial bladder tumors: The importance of recurrence pattern following initial resection
61. Consensus review of clinical utility of DNA cytometry in bladder cancer
62. DNA profile and tumor progression in patients with superficial bladder tumors
63. Clinical DNA flow cytometry
64. Prognostic significance of DNA ploidy in Ta/T1 bladder cancer: A Southwest Oncology Group study
65. Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer
66. Prognostic markers in bladder cancer: A contemporary review of the literature
67. Nuclear overexpression of p53 protien in transitional cell bladder carcinoma: A marker for disease progression
68. A critical analysis of the use of p53 as a marker for management of bladder cancer
69. Blood group antigens in normal and neoplastic urothelium
70. Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma
71. Celt surface A,B or O (H) blood group antigens as an indicator of malignant potential in stage A bladder carcinoma
72. ABH isoantigens in stage 0 papillary transitional cell carcinoma of the bladder: Correlation with biological behavior
73. ABH antigens in transitional cell tumors of the urinary bladder - Correlation with clinical course
74. The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder
75. Prediction of bladder tumor invasion with the mixed cell agglutination test
76. Blood group antigen expression in bladder tumors: Immunohistochemical study of superficial bladder lesions
77. Blood group-related antigens in human urothelium: Enhanced expression of precursors, LeX and LeY determinants in urothelial carcinoma
78. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation
79. The Lewis X antigen as a predictor of tumor recurrence in high risk disease-free bladder cancer patients
80. Endoscopic applications of laser energy
81. Endoscopic Nd:YAG laser application for destroying bladder tumors
82. Laser surgery for transitional-cell carcinoma
83. Use of the holmium: YAG laser for treatment of superficial bladder carcinoma
84. Hematoporphyrin derivative: A possible aid in the diagnosis and therapy of carcinoma of the bladder
85. The role of photodynamic therapy in the treatment of recurrent superficial bladder cancer
86. Oxygen dependence of hematoporphyrin derivative-induced photoinactivation of Chinese hamster cells
87. An overview of the treatment of superficial bladder cancer
88. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: Results of a European Organization for research on treatment of cancer, randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin
89. The effect of intravesical thiotepa on tumor recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer: A further report with long-term follow-up of a Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer
90. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder
91. Thiotepa pharmacokinetics during intravesical chemotherapy: The influence of dose and volume of instillate on systemic uptake and dose rate to the tumor
92. Hematologic effects of intravesical thiotepa therapy for bladder carcinoma
93. Complications of intravesical chemotherapy
94. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma
95. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer
96. A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thiotepa
97. The effects of intravesical instillation of thio-tepa on the recurrence rate of bladder tumors
98. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: An EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone
99. Influence of thiopeta and doxorubicin instillation at the time of transurethral surgical treatment of bladder cancer on tumor recurrence: A prospective, randomized, double blind, controlled trial
100. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa
101. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer: An MRC study
102. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer - Intravesical thio-TEPA versus oral UFT
103. Long-term results of intravesical therapy for superficial bladder cancer
104. Apparent failure of current intravesical chemotherapy prophlaxis to influence the long-term cause of superficial transitional cell carcinoma of the bladder
105. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer
106. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer: Prospective, randomized controlled studies of the Japanese Urological Cancer Research Group
107. A randomized trial of doxorubicin and immunotherapy with Bacillus Calmette-Guérin for transitional-cell carcinoma of the bladder
108. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer
109. Natural history and treatment of low and high risk superficial bladder tumors
110. Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-fluorouracil after surgery for superficial bladder cancer
111. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and tranurethral resection alone
112. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): A randomized prospective study
113. Dermatitis due to intravesical mitomycin C: A delayed type hypersensitivity reaction?
114. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma: Results of a controlled prospective study in 58 patients
115. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor
116. The effect of intravesical mitomycin on recurrence of newly diagnosed superficial bladder cancer: A further report with 7 years of follow-up
117. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: Transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guérin
118. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: Short- and long-term follow-up
119. The management of superficial bladder cancer
120. Long-term results of intravesical prevention of recurrence with mitomycin C and Adriamycin in patients with superficial bladder cancer
121. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder
122. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single- stage Ta, T1 papillary carcinoma of the bladder
123. Intravesical 4′-epidoxorubicin (epirubicin) versus bacillus Calmette-Guérin: A controlled prospective study on the prophylaxis of superficial bladder cancer
124. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder
125. Intravesical instillation of epirubicin: Effect on tumor recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour
126. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: A prospective, randomized controlled study
127. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: A multicenter randomized trial
128. A randomized study of short versus long-term intravesical epirubicin instillation for superficial bladder cancer
129. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: Long-term results of a Euopean Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone
130. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 Bladder Cancer
131. Active immunotherapy for acute lymphoblastic leukaemia
132. Use of BCG in the treatment of human neoplasms: A review
133. Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder
134. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors
135. Strategy for improving therapy of superficial bladder cancer
136. Murine bladder carcinoma cells present antigen to BCG specific CD4+ T-cells
137. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer
138. Improving the safety of BCG immunotherapy by dose reduction
139. Dose response to bacillus Calmette-Guérin in the treatment of superficial bladder cancer
140. Evolution and clinical significance of the T-cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus CalmetteGuérin during intravesical treatment of superficial bladder cancer
141. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
142. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study
143. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumors
144. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
145. Two courses of intravesical bacillus Calmette-Guérin for transitional cell carcinoma of the bladder
146. Bacillus Calmette-Guérin immunotherapy for bladder cancer
147. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors
148. Long-term effect of intravesical bacillus Calmette-Guérin on flat carcinoma in situ of the bladder
149. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: Is it effective?
150. Carcinoma in situ
151. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: A Southwest Oncoclogy Group Study
152. The use of bacillus Calmette-Guérin in the therapy of bladder carcinoma in situ
153. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer
154. A low dose bacillus Calmette-Guérin regimen in superficial bladder cancer therapy: Is it effective?
155. Single course versus maintenance bacillus Calmette-Guérin therapy for superficial bladder tumors: A prospective randomized trial
156. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer
157. Complications of bacillus Calmette-Guérin immunotherapy
158. Incidence and treatment of complications of bacillus Calmette-Guérin in intravesical therapy in superficial bladder cancer
159. Immunologic reduction of bladder cancer recurrence rate
160. Immunotherapy in bladder cancer with keyhole-limpet hemocyanin a randomized study
161. Topical immunotherapy (KLH) vs chemotherapy (ethoglucid) in prevention of recurrence of superficial bladder cancer: A prospective randomized study
162. A randomized controlled study of intravesical alpha-2b interferon in carcinoma in situ of the bladder
163. BCG plus interferon alpha 2b in patients with superficial bladder cancer
164. Co-administration of INF alpha 2b with low dose is effective in patients with superficial bladder cancer who failed BCG
165. Megadose vitamins in bladder cancer: A double-blind clinical trial
166. Indications for early cystectomy
167. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction
168. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder
169. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy
170. Results of contemporary radical cystectomy for invasive bladder cancer: A clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification
171. Radical cystectomy for carcinoma of the bladder: Critical evaluation of the results in 1026 cases
172. Residual tumor discovered in routine transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder
173. Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: Long-term results
174. Correlation between p53 over expression and response to bacillus Callmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer
175. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guerin treatment
176. Indications for early cytectomy
177. The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, P1S and P2)